Thomas Sau-Yan Chan

Learn More
Two tri-axial accelerometers were placed on the wrists (one on each hand) of the patients with Parkinson's disease (PD) and a non-PD control group. Subjects were asked to perform three of the upper extremity motor function tasks from the Unified Parkinson's Disease Rating Scale (UPDRS) test. The tasks were: 1) finger tapping, 2) opening and closing of(More)
PURPOSE Patterns of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) -negative, antihepatitis B core antigen antibody (anti-HBc) -positive patients with lymphoma receiving rituximab-containing chemotherapy have not been well described. PATIENTS AND METHODS HBsAg-negative, anti-HBc-positive Chinese patients with undetectable(More)
Dear Editor, Antibody treatment targeting the programmed cell death protein 1 (PD1) is rapidly becoming an important strategy against Hodgkin lymphoma [1]. However, recipients of allogeneic haematopoietic stem cell transplantation (HSCT) are typically excluded from clinical trials. Negative signalling via PD1 after ligation with its ligand PDL1 is regarded(More)
Acute leukemia relapsing after allogeneic hematopoietic stem cell transplantation (HSCT) has dismal outcome. Consecutive consenting patients (acute myeloid leukemia: N = 71; acute lymphoblastic leukemia: N = 37), at a median age of 37 (16-57) years, who had relapsed 7.9 (1.3-132) months post-HSCT, were treated with three cytarabine-based intensive regimens(More)
The frequency of breakthrough invasive fungal diseases (IFDs) during echinocandin therapy is unclear. We retrospectively analyzed 534 hematologic patients treated with echinocandin (caspofungin, N = 55; micafungin, N = 306; anidulafungin, N = 173). Four proven IFDs were found, caused by Candida parapsilosis (N = 2), C. parapsilosis and Candida glabrata (N =(More)
Natural killer (NK)/T-cell lymphomas failing L-asparaginse regimens have no known salvage and are almost invariably fatal. Seven male patients with NK/T-cell lymphoma (median age, 49 years; range, 31-68 years) for whom a median of 2 (range, 1-5) regimens (including l-asparaginase regimens and allogeneic hematopoietic stem-cell transplantation [HSCT] in 2(More)
Dear Editor, Relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation (HSCT) has a dismal prognosis, despite the use of chemotherapy, donor lymphocyte infusion (DLI) or second HSCT [1]. For relapses within 1 year postHSCT, current strategies lead to survival in fewer than 10% of cases [1, 2]. Immunotherapy including the use of(More)
Dear Editor, B cell lymphomas with concurrent rearrangements of BCL2 andMYC are often referred to as double-hit lymphomas [1]. It is an aggressive neoplasm characterized by rapid lymphoma cell proliferation, resulting in a large tumor load, B-symptoms, and a high incidence of bone marrow infiltration and central nervous system (CNS) involvement [1].(More)
Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100–200 mg, every 3 weeks). Complete response (CR) was achieved in four patients (80%), after a median cumulative dose of merely 495 (300–800)(More)
BACKGROUND Reactivation of latent herpes viruses occurs with immunosuppression. Alemtuzumab is an antibody targeting CD52, which is expressed on all B- and T-cells. Treatment with alemtuzumab leads to profound T-cell suppression, and reactivation of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) occurs. Valganciclovir is used as an anti-CMV prophylaxis(More)